CD20 Molecule Background B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1 ...

Current therapies target the CD20 + protein on the surface of cancerous B cells but with limited efficacy. A newly developed antibody-based molecule targets B-non-Hodgkin lymphoma by engaging ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi ...

The recently published article in Science by the Genentech team presents the structure of CD20 in complex with the therapeutic monoclonal antibody RTX. This study underscores the significance of ...

These target various cytokines such as TNF-α, IL-1, IL-6, block T-cell costimulation and act against the CD20 molecule present on B cells. It is the most common idiopathic inflammatory arthritis ...

SAN DIEGO, CA, USA & SHANGHAI, China I January 06, 2024 I Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming ...

The molecule itself has four components, including three that activate natural killer cells. An additional anti-CD20 antibody fragment directly targets the cancer. By design, the molecule ...